Banished from the institute he founded, separated from his lab materials, Tom Curran sues Children’s Mercy

Whistleblower lawsuit alleges wrongful firing

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Nov. 6, 2023, was a bad day for Tom Curran, a charming scientist with a lilting Scottish brogue and the lifelong dream of curing childhood cancers.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Patients saw a 35% reduced risk of disease progression or death for Trodelvy (sacituzumab govitecan-hziy) plus Keytruda (pembrolizumab) (n=221) versus standard of care Keytruda plus chemotherapy (n=222), according to the positive phase III ASCENT-04/KEYNOTE-D19 study evaluating the combination of Trodelvy plus Keytruda in first-line PD-L1+ (CPS ≥10) metastatic triple-negative breast cancer. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login